Cellectis ADR (NASDAQ:CLLS) has a beta value of 3.25 and has seen 77558.0 shares traded in the last trading session. The company, currently valued at $111.74M, closed the last trade at $1.55 per share which meant it gained $0.02 on the day or 1.33% during that session. The CLLS stock price is -118.06% off its 52-week high price of $3.38 and 9.03% above the 52-week low of $1.41. If we look at the company’s 10-day average daily trading volume, we find that it stood at 96730.0 shares traded. The 3-month trading volume is 139.98K shares.
The consensus among analysts is that Cellectis ADR (CLLS) is Buy stock at the moment, with a recommendation rating of 1.57. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.21.
Cellectis ADR (NASDAQ:CLLS) trade information
Sporting 1.33% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CLLS stock price touched $1.55 or saw a rise of 3.73%. Year-to-date, Cellectis ADR shares have moved -13.89%, while the 5-day performance has seen it change 1.31%. Over the past 30 days, the shares of Cellectis ADR (NASDAQ:CLLS) have changed -5.49%. Short interest in the company has seen 0.22 million shares shorted with days to cover at 0.93.
Cellectis ADR (CLLS) estimates and forecasts
The company’s shares have lost -24.39% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 510.04%.
6 analysts offering their estimates for the company have set an average revenue estimate of 20.48M for the current quarter. 3 have an estimated revenue figure of 11.17M for the next ending quarter. Year-ago sales stood 1.86M and 5.97M respectively for this quarter and the next, and analysts expect sales will grow by 1,002.83% for the current quarter and 510.04% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.69% over the past 5 years. Earnings growth for 2025 is a modest 69.99% while over the next 5 years, the company’s earnings are expected to increase by 34.25%.
CLLS Dividends
Cellectis ADR is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cellectis ADR (NASDAQ:CLLS)’s Major holders
The top two institutional holders are LONG FOCUS CAPITAL MANAGEMENT, LLC with over 4.62 million shares worth more than $8.63 million. As of 2024-06-30, LONG FOCUS CAPITAL MANAGEMENT, LLC held 5.1161% of shares outstanding.
The other major institutional holder is CAPITAL INTERNATIONAL INVESTORS, with the holding of over 1.85 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.46 million and represent 2.0485% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Smallcap World Fund and Delaware Group Equity Fds IV-Delaware Healthcare Fund. As of Sep 30, 2024, the former fund manager holds about 2.56% shares in the company for having 1.85 shares of worth $2.87 million while later fund manager owns 226.88 shares of worth $0.35 million as of Sep 30, 2024, which makes it owner of about 0.31% of company’s outstanding stock.
